Michael J. Grant

521 total citations · 1 hit paper
15 papers, 284 citations indexed

About

Michael J. Grant is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Michael J. Grant has authored 15 papers receiving a total of 284 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pulmonary and Respiratory Medicine, 7 papers in Oncology and 6 papers in Surgery. Recurrent topics in Michael J. Grant's work include Lung Cancer Treatments and Mutations (5 papers), Cancer Immunotherapy and Biomarkers (3 papers) and Bladder and Urothelial Cancer Treatments (2 papers). Michael J. Grant is often cited by papers focused on Lung Cancer Treatments and Mutations (5 papers), Cancer Immunotherapy and Biomarkers (3 papers) and Bladder and Urothelial Cancer Treatments (2 papers). Michael J. Grant collaborates with scholars based in United States, Italy and United Kingdom. Michael J. Grant's co-authors include Sarah B. Goldberg, Roy S. Herbst, April K.S. Salama, Nicholas C. DeVito, Arthur J. Nam, Yvonne M. Rasko, Colton H. McNichols, Scott D. Lifchez, Zenta Walther and Katerina Politi and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Michael J. Grant

11 papers receiving 282 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC

2021 161 citations Michael J. Grant, Roy S. Herbst et al. Nature Reviews Clinical Oncology profile →

Peers

Countries citing papers authored by Michael J. Grant

Since Specialization

Citations

This map shows the geographic impact of Michael J. Grant's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael J. Grant with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael J. Grant more than expected).

Fields of papers citing papers by Michael J. Grant

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael J. Grant. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael J. Grant. The network helps show where Michael J. Grant may publish in the future.

Co-authorship network of co-authors of Michael J. Grant

This figure shows the co-authorship network connecting the top 25 collaborators of Michael J. Grant. A scholar is included among the top collaborators of Michael J. Grant based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael J. Grant. Michael J. Grant is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work	Indexed citations
1	ERBB2 mutations and association with molecular phenotype in urothelial carcinoma. 2024 ·Journal of Clinical Oncology ·(unknown), Talal El Zarif, Paul Stockhammer, (unknown), (unknown), (unknown), (unknown), Emre Yekedüz, Amin H. Nassar, Gwo‐Shu Mary Lee, Sylvan C. Baca, Toni K. Choueiri, Michael J. Grant, Joaquim Bellmunt	0
2	Efficacy of Antibody Drug Conjugates Alone and in Combination with other Agents in Metastatic Urothelial Carcinoma: A Scoping Review 2024 ·Bladder Cancer ·Michael J. Grant, Paul Stockhammer, (unknown), Zsuzsanna Németh, Daniel P. Petrylak	0
3	Telehealth and Outcomes in Patients With Cancer 2024 ·The Cancer Journal ·Michael J. Grant, (unknown)	0
4	The Evolving Role for Systemic Therapy in Resectable Non-small Cell Lung Cancer 2023 ·Hematology/Oncology Clinics of North America ·Michael J. Grant, Gavitt A. Woodard, Sarah B. Goldberg	1
5	Co-Occurring Alterations in Multiple Tumor Suppressor Genes Are Associated With Worse Outcomes in Patients With EGFR-Mutant Lung Cancer 2023 ·Journal of Thoracic Oncology ·Paul Stockhammer, Michael J. Grant, Anna Wurtz, Giorgia Foggetti, Francisco Expósito, Jianlei Gu, Hongyu Zhao, Jungmin Choi, (unknown), Fangyong Li, Zenta Walther, Julia Dietz, (unknown), Scott Gettinger, Katerina Politi, Sarah B. Goldberg	30
6	Association of alterations in multiple tumor suppressor genes with poor outcomes in patients with EGFR-mutant lung cancer. 2023 ·Journal of Clinical Oncology ·Paul Stockhammer, Michael J. Grant, Anna Wurtz, Giorgia Foggetti, Francisco Expósito, Jianlei Gu, (unknown), Fangyong Li, Zenta Walther, Scott Gettinger, Katerina Politi, Sarah B. Goldberg	0
7	Biochemical and structural basis for differential inhibitor sensitivity of EGFR with distinct exon 19 mutations 2022 ·Nature Communications ·(unknown), David Lu, Michael J. Grant, Steven E. Stayrook, Manali Phadke, Zenta Walther, Sarah B. Goldberg, Katerina Politi, Mark A. Lemmon, Kumar Dilip Ashtekar, Yuko Tsutsui	17
8	Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC breakdown → 2021 ·Nature Reviews Clinical Oncology ·Michael J. Grant, Roy S. Herbst, Sarah B. Goldberg	161
9	What do Emergency Physicians Know About Immune Checkpoint Inhibitor-Related Toxicities: A Brief Report 2021 ·International Journal of Cancer Management ·(unknown), (unknown), Michael J. Grant, Francesca Jackson‐Spence, (unknown), (unknown), Jie Min Lam, (unknown), Deborah Enting, Thomas Powles, Bernadett Szabados	2
10	Treatment with Foscarnet after Allogeneic Hematopoietic Cell Transplant (Allo-HCT) Is Associated with Long-Term Loss of Renal Function 2020 ·Biology of Blood and Marrow Transplantation ·Gena G. Foster, Michael J. Grant, Samantha Thomas, Blake Cameron, (unknown), Kelly Corbet, (unknown), (unknown), Mitchell E. Horwitz	6
11	HSCT-GAVE as a Manifestation of Chronic Graft versus Host Disease: A Case Report and Review of the Existing Literature 2018 ·SHILAP Revista de lepidopterología ·Michael J. Grant, Mitchell E. Horwitz	1
12	Checkpoint Inhibitor use in Two Heart Transplant Patients with Metastatic Melanoma and Review of High-Risk Populations 2018 ·SHILAP Revista de lepidopterología ·Michael J. Grant, Nicholas C. DeVito, April K.S. Salama	20
13	Cosmetic Surgery Training in Plastic Surgery Residency Programs 2017 ·Plastic & Reconstructive Surgery Global Open ·Colton H. McNichols, (unknown), (unknown), (unknown), Michael J. Grant, Scott D. Lifchez, Arthur J. Nam, Yvonne M. Rasko	30
14	A curious case of stress fracture in a transsexual athlete 2016 ·BMJ Case Reports ·(unknown), Michael J. Grant, Prakash Chandran	2
15	Radiation-induced liver disease as a mimic of liver metastases at serial PET/CT during neoadjuvant chemoradiation of distal esophageal cancer 2014 ·Abdominal Imaging ·Michael J. Grant, Ryne A. Didier, (unknown), (unknown), John G. Hunter, Charles R. Thomas, Fergus V. Coakley	14

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact